应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
GCVRZ Sanofi
退市 08-11 04:28:23 EDT
0.8711
+0.0000
0.00%
最高
0.8711
最低
0.8711
成交量
0.00
今开
0.8711
昨收
0.8711
日振幅
0.00%
总市值
10.92亿
流通市值
9.71亿
总股本
12.54亿
成交额
0.00
换手率
0.00%
流通股本
11.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
中国生物制药(01177)与Sanofi就罗伐昔替尼订立独家授权协议
智通财经 · 03-04
中国生物制药(01177)与Sanofi就罗伐昔替尼订立独家授权协议
美国OTC市场Sanofi盘中异动 早盘股价大跌3.19%
市场透视 · 01-02
美国OTC市场Sanofi盘中异动 早盘股价大跌3.19%
ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
动脉网 · 2025-12-16
ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。
金融界 · 2025-01-30
Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。
加载更多
公司概况
公司名称：
Sanofi
所属市场：
NASDAQ
上市日期：
--
主营业务：
Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。
发行价格：
--
{"stockData":{"symbol":"GCVRZ","market":"US","secType":"STK","nameCN":"Sanofi","latestPrice":0.8711,"timestamp":1786392000000,"preClose":0.8711,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":1114622547,"shares":1254041488,"eps":2.519335,"marketStatus":"退市","change":0,"latestTime":"08-11 04:28:23 EDT","open":0.8711,"high":0.8711,"low":0.8711,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.519335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786455000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8711,"dividendRate":4.027632,"volumeRatio":0},"requestUrl":"/m/hq/s/GCVRZ","defaultTab":"news","newsList":[{"id":"2616774663","title":"中国生物制药(01177)与Sanofi就罗伐昔替尼订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2616774663","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616774663?lang=zh_cn&edition=full","pubTime":"2026-03-04 06:19","pubTimestamp":1772576365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，集团附属公司正大天晴药业集团股份有限公司已与Sanofi S.A.的一间全资附属公司就集团的JAK/ROCK抑制剂罗伐昔替尼在全球的开发、生产及商业化订立独家授权协议。根据协议条款，该集团将授予Sanofi在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","HK0000165453.HKD","BK1191","BK1515","BK4007","IE00BZ08YS42.EUR","01177","SNYNF","IE00BZ08YR35.GBP","BK1589","GCVRZ","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600096814","title":"美国OTC市场Sanofi盘中异动 早盘股价大跌3.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600096814","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2600096814?lang=zh_cn&edition=full","pubTime":"2026-01-02 22:46","pubTimestamp":1767365195,"startTime":"0","endTime":"0","summary":"北京时间2026年01月02日22时46分，美国OTC市场Sanofi股票出现波动，股价急速跳水3.19%。截至发稿，该股报94.19美元/股，成交量300股，换手率0.00%，振幅0.00%。美国OTC市场Sanofi股票所在的制药行业中，整体跌幅为0.90%。美国OTC市场Sanofi公司简介：赛诺菲专注于免疫学、疫苗和罕见病领域的药物开发和销售。总收入的约 45% 来自美国，20% 来自欧洲，6% 来自中国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102224635a6ebf0c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102224635a6ebf0c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GCVRZ","BK4007","SNYNF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592514799","title":"ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592514799","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2592514799?lang=zh_cn&edition=full","pubTime":"2025-12-16 14:41","pubTimestamp":1765867260,"startTime":"0","endTime":"0","summary":"The total potential value of the agreement is up to $1.04 billion. ADEL will receive a non-refundable upfront payment of $80 million and is eligible to receive additional payments contingent upon the achievement of specified development and commercial milestones. Additionally, ADEL is entitled to receive tiered royalties on net sales ranging up to double-digit percentages..协议的总潜在价值高达 10.4 亿美元。ADEL spearheaded the entire discovery and preclinical development of ADEL-Y01 using its proprietary neural disease research and development platform. Since 2020, ADEL has been co-developing the asset through a joint research and development agreement with Oscotec Inc. Currently, ADEL-Y01 is undergoing a global Phase 1 clinical trial under an Investigational New Drug application approved by the U.S.ADEL利用其专有的神经疾病研发平台，引领了ADEL-Y01的整个发现和临床前开发过程。自2020年起，ADEL通过与Oscotec Inc.签订的联合研发协议共同开发该资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SNYNF","GCVRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507107986","title":"Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507107986","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507107986?lang=zh_cn&edition=full","pubTime":"2025-01-30 17:13","pubTimestamp":1738228394,"startTime":"0","endTime":"0","summary":"Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30171347906752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GCVRZ","SNY","SNYNF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.0472},{"period":"6month","weight":0.1172},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","exchange":"NASDAQ","name":"Sanofi","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sanofi(GCVRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sanofi(GCVRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sanofi,GCVRZ,Sanofi股票,Sanofi股票老虎,Sanofi股票老虎国际,Sanofi行情,Sanofi股票行情,Sanofi股价,Sanofi股市,Sanofi股票价格,Sanofi股票交易,Sanofi股票购买,Sanofi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sanofi(GCVRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sanofi(GCVRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}